| Name | Title | Contact Details |
|---|
At BioNTech we believe that every cancer patient’s treatment should be individualized. Our vision is to provide patient-specific immunotherapies worldwide.
Cellular Genomics, Inc. is a Branford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
EntreMed is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GeneSage is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.